Eyam Health

What Eyam Health does

Eyam Health is a late preclinical-stage Canadian genetic-medicine platform company headquartered in Vancouver, BC, founded in 2020 around the Gemini self-amplifying DNA (saDNA) and self-amplifying RNA (saRNA) delivery platform invented at the University of British Columbia by Dr. Wilfred A. Jefferies. The Gemini platform produces durable therapeutic protein expression (6+ months for Gemini-D/saDNA, ~42 days for Gemini-R/saRNA) from a single, non-viral, carrier-free, room-temperature-stable dose, supporting up to 5 open reading frames per construct and avoiding the anti-PEG and anti-capsid immunity that limit redosing with mRNA-LNP and viral vectors. Paired with the proprietary Jennerator AI engine — a vector-aware immunoinformatics design tool built by bioinformatics lead Dr. Paolo Ribeca — the company pairs AI-designed payloads with a delivery architecture validated across mouse, canine, and Yorkshire pig models, with NHP studies underway.

Eyam generates revenue through a B2B platform-licensing model: milestone-gated feasibility studies with option-to-license, indication/geography platform licenses with tiered royalties, joint co-development partnerships, and inbound product licensing of de-risked programs such as the CaV1.4/OX40 oncology antibody option acquired from UBC. Non-dilutive grant funding from the Bill & Melinda Gates Foundation, NRC IRAP, and Innovate UK supports preclinical infectious-disease and global-health programs, while enterprise customers include a Top-5 animal health company and Medicines for Malaria Venture (MMV). Go-to-market is enterprise-focused, led by VP Strategic Partnerships Dr. Pamela Housh with conference presence at JPM Healthcare, BIO International, World Vaccine Congress, and TIDES USA; the company has explicit capacity for one new platform partnership in 2026 and is concurrently pursuing a Series A financing.

Name

Eyam Health

Legal name

Eyam Health

Website

https://eyamhealth.com

Company type

Private

Founded year

2020

Operating status

Operating

Headcount range

11–50 employees

Short description

Eyam Health is a Vancouver-based preclinical genetic-medicine platform company that licenses its Gemini self-amplifying DNA/RNA delivery technology and Jennerator AI payload-design engine to pharmaceutical, biotech, and global-health partners for vaccines, monoclonal antibodies, and therapeutics.

Ownership category

akta.pro rank

Product category

Genetic Medicine Delivery Platform

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

RNA Therapeutics Platforms & Design (sequence design, target ID/validation, AI/bioinformatics) (HLAAADAG)

Keywords

• Self-amplifying DNA platform
• Genetic medicine delivery
• Vaccine platform technology
• AI payload design
• Monoclonal antibody therapeutics

Headquarters

HQ city

Surrey

HQ country

Canada

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Others

Revenue model

1. Platform Licensing: Licensing Gemini platform to pharmaceutical and biotech companies by indication/geography with tiered royalties. Partners can apply the technology to their therapeutic area at scale.
2. Feasibility Studies: Milestone-gated feasibility studies with option-to-license. Eyam runs assays to evaluate Gemini against partner's proprietary program. Can be structured as MTA or non-commercial licensing agreement.
3. Co-Development Partnerships: Joint R&D partnerships combining partner's clinical/regulatory capabilities with Gemini delivery. Revenue generated through milestone payments and eventual royalties.
4. Product Licensing: In-licensing de-risked programs (e.g., CaV1.4 oncology) for further development.
5. Partnership Revenue: Revenue from strategic partnerships including feasibility studies and milestone payments. Eyam achieved revenue in year four of operations, ahead of typical biotech timelines.
6. Grant Funding: Non-dilutive funding from global health organizations including Gates Foundation for preclinical development in infectious disease and global health applications.

Pricing tiers

Go-to-market motion2 records

Distribution channels4 records

Marketing channels5 records

Core offering

Eyam Health develops and licenses the Gemini self-amplifying DNA (saDNA) and self-amplifying RNA (saRNA) delivery platform, paired with the Jennerator AI engine that designs and optimizes genetic payloads. The platform enables durable, multi-payload, redosable therapeutic protein expression from a single, non-viral, carrier-free, thermostable injection — applicable to vaccines, monoclonal antibodies, and therapeutic proteins across infectious disease, oncology, chronic disease, and animal health. Eyam monetizes the platform through feasibility studies, platform licensing, co-development partnerships, and product licensing.

Product overview

Eyam Health is a late preclinical-stage platform company advancing genetic medicines through two integrated technologies: the Gemini platform (a self-amplifying DNA/RNA delivery system) and the Jennerator AI engine (an AI-driven payload design tool). Gemini enables durable protein expression from a single, thermostable injection without lipid nanoparticles or viral vectors, available in two variants: Gemini-D (saDNA, 6+ months expression) for therapeutics and Gemini-R (saRNA, ~42-day expression) for vaccines. Jennerator AI designs and optimizes the genetic payloads that Gemini delivers. Together, these platforms span infectious disease, oncology, chronic disease, and animal health applications.

Differentiator

Problem solved

Functional benefit

Brands

• Gemini: Self-amplifying DNA (saDNA) expression platform that enables sustained production of therapeutic proteins from a single, thermostable, non-viral dose
• Jennerator
• Sentinel AI

Products and services

• Gemini Platform A binary self-amplifying DNA (saDNA) and self-amplifying RNA (saRNA) expression platform that enables the body to produce therapeutic proteins from a single, room-temperature-stable, non-viral injection without lipid nanoparticles or viral capsids. Supports multi-payload constructs (up to 5 ORFs / ~16-20 kb) and is redosable. Licensed to pharmaceutical, biotech, global-health, and animal-health partners.
• Gemini-D (saDNA) Self-amplifying DNA variant of the Gemini platform designed for long-duration (6+ months preclinical) therapeutic protein expression. Ideal for single-dose therapeutics with integration below FDA limits. Best suited for chronic disease and global health applications where durability and ambient-temperature stability matter.
• Gemini-R (saRNA) Self-amplifying RNA variant of the Gemini platform offering approximately 42-day expression with zero genomic integration. Designed for prime-boost vaccination strategies and vaccine applications, where durable but non-integrating expression is desired.
• Jennerator AI Engine Vector-aware AI-driven immunoinformatics engine that designs and optimizes genetic payloads (proteins or antibodies) for maximum expression and durability. Predicts epitopes, optimizes HLA/MHC binding, and tunes payload design from inception around the delivery constraints of Gemini, accelerating vaccine and therapeutic candidate development for partners.
• Platform Licensing (by indication/geography) Licensing of the Gemini platform to pharmaceutical and biotech partners by indication or geography, with tiered royalties. Enables partners to apply Eyam's saDNA/saRNA delivery and Jennerator AI design capability to their therapeutic area at scale.
• Feasibility Studies Milestone-gated evaluation studies with an option-to-license, structured as an MTA or non-commercial licensing agreement. Eyam runs the assays to evaluate Gemini against a partner's proprietary program, de-risking the partnership before broader licensing or co-development.
• Co-Development Partnerships Joint R&D partnerships that combine a partner's clinical and regulatory capabilities with Eyam's Gemini delivery platform, generating milestone payments and eventual royalties from jointly developed assets.
• CaV1.4 Oncology Program (in-licensed) Option to license patents from UBC for an antibody biologic cancer therapeutic targeting leukemia and lymphoma via the OX40 pathway; included as a de-risked product-licensing opportunity for partners seeking an IND-directed asset.

Quantifiable outcome

• 6+ months of sustained antibody expression from a single dose in preclinical studies
• +5 more outcomes

Named customers3 records

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature5 records

Partnerships

Eight partnerships are on record, tiered minor, major and core.

• Creative Destruction Lab (CDL)minorOthers · 11 June 2026CDL is a nonprofit objectives-based program for science- and technology-based companies. Eyam graduated from CDL Vancouver Biomedical stream after nine months, gaining mentorship, strategic insights, and network access. CDL ventures have generated over CAD $55 billion in equity value.
• iiDiagnostics (iiDX)majorStrategic or Co-development Partner · 15 January 2026UK-Canada collaboration valued at £750,000 to advance next-generation vaccine development using automated organoid models. Combines Eyam's Gemini saDNA delivery platform and Jennerator AI design engine with LSTM's organoid automation technology at Liverpool's Robotic Infection Research Laboratory. Initial program focuses on universal SARS-CoV-2 vaccine.
• Liverpool School of Tropical Medicine (LSTM)majorStrategic or Co-development Partner · 15 January 2026Through iiCON consortium, LSTM provides advanced organoid automation technology for the UK-Canada collaboration. Project will be carried out in LSTM's state-of-the-art Liverpool Robotic Infection Research Laboratory, one of the first Category Three Level robotic laboratories in the UK.
• Infection Innovation Consortium (iiCON)majorStrategic or Co-development Partner · 15 January 2026iiCON is a global £250 million collaborative infectious disease R&D programme bringing together industry, academia, and NHS. Through iiCON partner iiDX, Eyam accesses LSTM's Robotic Infection Research Laboratory for automated human-relevant vaccine testing.
• Medicines for Malaria Venture (MMV)coreStrategic or Co-development Partner · 21 July 2025Strategic research partnership with MMV to discover and evaluate next-generation monoclonal antibody-based approaches for affordable, long-acting malaria therapies. Collaboration aims to create a globally deployable malaria prevention mAb backed by Gemini's single-dose, ambient-temperature-stable delivery. Partnership targets less than $1 per dose for malaria prevention.
• Top 5 Animal Health CompanymajorStrategic or Co-development Partner · 18 July 2025Advancing partnership with leading animal health company into next phase of joint development program focused on antibody-based therapeutics for chronic conditions in companion animals. Leverages Gemini delivery platform to increase durability and production of monoclonal antibodies. Study evaluating performance and tolerability in canine model.
• MitacsminorStrategic or Co-development Partner · 31 May 2023Partnership with Mitacs to establish Sentinel AI: Office of Pandemic Preparedness research facility. Supports post-doctoral scientific research and development of Jennerator bioinformatics platform through AI and machine learning applied to omics data.
• University of British Columbia (UBC)coreOEM/ Whitelabel/ Licensing Partner · 27 September 2022Eyam acquired an option to license patents related to antibody biologic cancer therapeutic from UBC. The technology targets leukemia and lymphoma and belongs to an emerging group of biologic drugs. Includes portfolio of biologic patents and patent applications for further development and commercialization.

Scale indicators14 records

Recent moves5 records

Expansion highlights6 records

Emerging players

• Verve Therapeutics: Verve is developing in vivo gene editing medicines for cardiovascular disease using LNP-encapsulated base editors. While it uses lipid nanoparticles rather than naked delivery, it is a comparable in vivo genetic-medicine platform targeting durable protein modulation and competes for partner interest in chronic-disease indications.
• Tessera Therapeutics: Tessera is developing Gene Writing and RNA Writing technologies for in vivo genetic medicine, with a focus on non-viral delivery and redosable gene modification. It is a comparable emerging platform in the non-viral genetic-medicine space.

Broad incumbents

• Moderna: Moderna is the leading mRNA-LNP platform company with multiple approved vaccines and a broad pipeline in oncology, rare disease, and infectious disease. It is the principal incumbent against which Eyam must differentiate on durability, redosability, and cost.
• BioNTech: BioNTech is a global mRNA therapeutics leader with a broad pipeline spanning infectious disease, oncology, and rare disease. Its scale, manufacturing infrastructure, and partnership reach make it the dominant broad incumbent in RNA-based genetic medicines.
• CureVac: CureVac is an mRNA technology company developing vaccines and therapeutics using both conventional and self-amplifying mRNA constructs. It is a broad incumbent in the RNA therapeutic space and a direct reference point for saRNA platform economics and clinical translation risk.

Direct peers

• Strand Therapeutics: Strand develops self-amplifying RNA therapies for cancer and other diseases using synthetic biology and AI-driven design. Its programmable saRNA platform directly parallels Eyam's Gemini approach and shares the same oncology and protein-replacement target indications.
• Generation Bio: Generation Bio develops non-viral, redosable genetic medicines using a DNA-based delivery platform (closed-ended DNA and cell-targeted lipid nanoparticles). It is the closest analog to Eyam's non-viral, carrier-free approach and shares the strategic thesis of avoiding AAV immune responses.
• Replicate Bioscience: Replicate is developing self-amplifying RNA (srRNA) therapeutics for oncology, immunology, and infectious disease. Its platform competes head-to-head with Gemini in the saRNA therapeutic space and shares the same redosing-and-durability narrative.
• Arcturus Therapeutics: Arcturus is a clinical-stage mRNA medicines company with a leading self-amplifying RNA (saRNA) platform for vaccines and therapeutics, including a partnered COVID-19 vaccine. It is the most direct competitor to Eyam's Gemini-R (saRNA) component and shares the same therapeutic-area overlap in vaccines and rare disease protein expression.

Others

• AbCellera Biologics: AbCellera is a clinical-stage antibody discovery platform that partners with pharma to identify therapeutic antibodies. It is a relevant ecosystem peer — and potential partner — for Eyam's monoclonal antibody programs delivered via Gemini.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/eyamhealth
• LinkedInlinkedin.com/company/eyamhealth

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds3 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Eyam Health